Melanoma patients and their families urged to speak up and put national spotlight on melanoma.
15 April 2021
Melanoma patients and their carers are being urged to participate in a ground-breaking survey which will shape the future of melanoma treatment, research, support and funding in Australia.
Melanoma Institute Australia and Melanoma Patients Australia are partnering to develop the country’s first ever landmark melanoma report: State of the Nation – A Report into Melanoma.
This comprehensive report will examine the issues currently facing melanoma patients and carers across Australia and make recommendations for policy change and investment to substantially improve outcomes for them as well as the wider Australian community.
‘Australia has the highest melanoma rates in the world, and this State of the Nation report will for the first times provide an indepth assessment of the far-reaching impacts of the disease across the country,’ said Melanoma Institute Australia CEO Matthew Browne.
‘It will provide the opportunity to revolutionise melanoma policy, funding, care and support services going forward, which will in the long term benefit all Australians for generations to come.’
Critical to developing State of the Nation- A Report into Melanoma is input from melanoma patients and their carers from across Australia. This is a call to action and we are asking people to take part in an online survey so we can understand their personal experiences.
‘The survey will provide invaluable insights into the impact of melanoma and the realities faced by patients and their families,’ said Melanoma Patients Australia CEO Victoria Beedle.
‘Your feedback is critical to the success of this State of the Nation report and I urge all melanoma patients and their families to invest just half an hour in completing this survey. By doing so, you will become part of the solution to this huge problem impacting communities across the country.’
Key areas being addressed in State of the Nation- A Report into Melanoma include:
- melanoma prevention and awareness, including the effectiveness of current campaigns and what more needs to be done
- early detection and diagnosis including the feasibility of a national skin screening program
- treatment options available and access to breakthrough therapies
- supportive care services during and after treatment
- issues facing survivors and their families after successful treatment
- palliative and end of life care
- research priorities, opportunities and challenges.
The State of the Nation report will be presented to government mid-year with the aim of guiding future policy and funding direction to help reduce the impact of melanoma on Australian society.
‘Every 30 minutes another Australian is told they have melanoma – so in the time it takes you to do the survey, another family will be embarking on the daunting and frightening melanoma journey,’ Matthew Browne added.
‘Completing the survey is a small investment of time with a potentially life-changing impact, and I thank all our wonderful melanoma community for stepping up to help.’
Former Executive Director of Melanoma Institute Australia Professor John Thompson awarded the prestigious 2018 RPA Foundation Research Medal.
Clinicians, patients and other stakeholders in the cancer community are invited to make submissions in support of the PBS listing for pembrolizumab.
The World Congress on Cancers of the Skin 2018 has featured many minds from MIA sharing their expertise and wealth of knowledge with over 1000 attendees from around the world.
Melanoma Institute Australia is delighted to announce the appointment of Matthew Browne as Chief Executive Officer (CEO).
It was a full house this week at Melanoma Institute Australia thanks to our ‘Melanoma in Practice: Nurse Conference’.
A new study from The University of Sydney shows that sunscreen reduces melanoma risk by 40 per cent when used from a young age.
Melanoma Institute Australia (MIA) has launched a free e-learning portal to educate healthcare professionals about the latest advances in melanoma diagnosis and treatment.
When David lost his life last year, he was 33, with three daughters under six.
Clinical trials are just that – trials in a clinical setting to evaluate the effectiveness or otherwise of individual and combination treatments.
Melanoma Institute Australia scooped the award pool at the Annual Scientific Meeting of the International Academy of Pathology.
Melanoma patients across Australia will benefit from the release of updated clinical care guidelines.
An American study has discovered a link between early detection and marital status in melanoma diagnosis.
An international course on melanoma pathology in Paris, France co-directed by Professor Richard Scolyer took place over the weekend.
Professor Richard Scolyer highlights the difficulties of diagnosis following the Australian Story feature program on Emma Betts.
Cancer Australia releases 'stage at diagnosis' data for top five incidence cancers – including melanoma
For the first time in Australia, national data has been released on cancer stage at diagnosis. This data explores the top five incidence cancers – female breast cancer, colorectal, lung, prostate cancers and melanoma.
'Dear Emma' - a tribute to the life and times of a young woman determined to raise awareness about melanoma.
Carole Renouf, CEO for MIA thanks Toyota for helping fuel ongoing melanoma research.
Fraser Dykes tackled the Kokoda Trail on an eight day trek in memory of his friend Mark 'Bod' Boddison.
Harvard’s Clinical Professor Martin Mihm and MIA’s Conjoint Medical Director Professor Richard Scoyler delivered a series of lectures on melanoma pathology in Vancouver, British Colombia this week at the world’s biggest annual pathology meeting.